Dr. Haifeng Wu – Medicinal chemistry – Best Researcher Award

Dr. Haifeng Wu - Medicinal chemistry - Best Researcher Award

Institute of Medicinal Plant Development, Chinese Academy of Medicinal Sciences & Peking Union Medical College - China 

Author Profile 

SCOPUS

Early academic pursuits 🎓

Dr. Haifeng Wu's academic journey began with a bachelor's degree in biochemical engineering from beijing university of chemical engineering in 2001. driven by a passion for plant biology and natural sciences, he pursued further studies at the northwest institute of plateau biology, chinese academy of sciences, where he earned his m.s. in botany in 2006. his curiosity and dedication to understanding ecological systems led him to complete his ph.d. in ecology from the same institute in 2009. this strong academic foundation set the stage for his distinguished career in medicinal plant research.

Professional endeavors 🏢

Dr. Wu is currently affiliated with the institute of medicinal plant development at the chinese academy of medicinal sciences & peking union medical college in beijing. in this role, he specializes in molecular modeling, chromatographical analysis, isolation, and modification of natural products. his expertise in biochemistry and plant biology has been instrumental in advancing research on medicinal plants and natural compounds. dr. wu’s work at this prestigious institution reflects his commitment to bridging traditional knowledge with modern scientific approaches to drug discovery.

Contributions and research focus 🔬

Throughout his career, dr. wu has made significant contributions to the fields of medicinal plant development and natural product chemistry. his research primarily focuses on molecular modeling, allowing for precise identification and modification of bioactive compounds in plants. he has developed cutting-edge techniques for Medicinal chemistry chromatographical analysis and isolation, contributing to the discovery of novel natural products with potential therapeutic applications. dr. wu’s work is pivotal in the search for new drugs derived from medicinal plants, targeting various diseases and health conditions.

Accolades and recognition 🏅

Dr. Wu’s achievements have not gone unnoticed in the scientific community. his innovative research and contributions to medicinal plant development have earned Medicinal chemistry him recognition and accolades, both within china and internationally. while specific awards are not listed, his role at one of the leading research institutions in china underscores his expertise and the respect he commands in his field.

Impact and influence 🌍

Dr. Wu’s research has a profound impact on both the scientific community and the pharmaceutical industry. his work on the molecular modeling and modification of natural products is crucial for the development of new, effective treatments. by isolating and understanding plant-based compounds, dr. wu is helping to unlock the medicinal potential of nature, influencing future research and contributing to global health advancements. his work supports sustainable medicinal plant use and Medicinal chemistry conservation, making it environmentally and socially relevant.

Legacy and future contributions 🔮

As a researcher deeply rooted in the exploration of natural products and medicinal plants, dr. wu’s legacy will be one of innovation and dedication to improving human health. his future contributions are expected to further enhance the understanding and utilization of plant-based compounds in modern medicine. dr. wu’s pioneering work will continue to inspire researchers and contribute to the discovery of novel therapeutic agents, ensuring his place as a key figure in the field of medicinal plant development.

Notable Publications

  • Title: UV light treatment (278 nm) for detoxification of aflatoxins and application in edible and medicinal herb coix seed
    Authors: Zou, L., Sun, Z., Li, Q., Ma, G., Xu, X.
    Journal: International Journal of Food Science and Technology, 2024, 59(6), pp. 3723–3734
  • Title: Asiaticoside exerts neuroprotection through targeting NLRP3 inflammasome activation
    Authors: He, Z., Hu, Y., Zhang, Y., Wu, H., Hu, W.
    Journal: Phytomedicine, 2024, 127, 155494
  • Title: Identifying potential Q-markers for quality evaluation of Zhenyuan capsule by integrating chemical analysis, network pharmacology, molecular docking, and molecular dynamics simulations
    Authors: Zhao, Z., Yang, Q., Ma, Y., Wu, H., Liu, X.
    Journal: Natural Product Research, 2024
  • Title: Phenolic constituents with antibacterial activity from Eleutherine bulbosa
    Authors: Sun, Z., Li, Q., Zhang, J., Xu, X., Ma, G.
    Journal: Fitoterapia, 2024, 172, 105787
  • Title: Molecular interaction of soybean protein and piperine by computational docking analyses
    Authors: Zhang, C., Niu, Z., He, Z., Gu, F., Hu, W.
    Journal: Food Hydrocolloids, 2024, 146, 109249

Prof. Jerzy trojan – Immuno – gene therapy – Excellence in Innovation

Prof. Jerzy trojan - Immuno - gene therapy - Excellence in Innovation

CEDEA/ICGT and INSERM/Univ. Paris-Saclay - France

Author Profile

ORCID

Early academic pursuits 🎓

Jerzy trojan completed his doctorate d’état ès sciences (hdr) at the prestigious sorbonne - p&m curie. during this formative period, he laid the groundwork for his future contributions to biomedical science, specifically in the field of cancerology. his early research endeavors, characterized by a rigorous scientific approach, focused on critical aspects of oncology and laid the foundation for his later groundbreaking work.

Professional endeavors 🏥

Jerzy has held various esteemed positions throughout his career, reflecting his commitment to advancing cancer research. he is currently a visiting professor at the insitm, cancer center, and paris-saclay university in villejuif, france, where he has been since 2019. before this, he served as president and research director at the international cancer gene therapy and oncology diagnostics center (ceadea) in bogota, colombia, and has also held prominent roles in institutions across the usa and europe, including case western reserve university and the sidney kimmel cancer center. these diverse experiences have equipped him with a comprehensive understanding of both the scientific and clinical aspects of cancer treatment.

Contributions and research focus 🔬

Dr. trojan is best known for establishing cancer gene therapy, particularly immuno-gene therapy, as a pivotal domain within oncology. his pioneering research, highlighted in publications from 1993, led to significant advancements in the treatment of glioblastoma, showcasing the therapeutic potential of gene therapy. Immuno - gene therapy additionally, he explored the intersection between neuro-ontogenesis and neuro-oncogenesis, identifying afp and igf-i as novel biomarkers, which have implications for understanding central nervous system differentiation and cancer progression.

Accolades and recognition 🏆

In recognition of his substantial contributions to biomedical science, jerzy was elected as a member of the prestigious french academy of medicine (anm) in paris in 2017. his extensive body of work includes nearly 370 publications, encompassing 140 articles, 102 book chapters, and four books, which have garnered over 3,500 Immuno - gene therapy citations. this impressive scholarly output underscores his impact and influence in the field of cancer research.

Impact and influence 🌍

Dr. trojan's research has significantly shaped the landscape of cancer therapy, particularly in immunotherapy. his establishment of immuno-gene therapy has opened new avenues for treating aggressive cancers, thus influencing both academic research and clinical practices. his work has not only contributed to theoretical Immuno - gene therapy advancements but has also informed practical applications that benefit patients facing challenging diagnoses.

Legacy and future contributions 🔮

With an enduring commitment to advancing cancer research, jerzy trojan continues to influence the field through his current role as a visiting professor and research director. his legacy is evident in the ongoing projects aimed at improving cancer treatment outcomes, particularly through innovative therapeutic strategies. as he continues to publish and mentor the next generation of researchers, his contributions will undoubtedly have a lasting impact on the future of oncology and gene therapy.

Notable Publications 

  • Title: Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment
    Author: J. Trojan et al.
    Journal: Medical Research and Its Applications, Vol. 6, Pages 114-127
    DOI: 10.9734/bpi/mria/v6/7520C
    Publication Date: June 3, 2024
  • Title: Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
    Author: J. Trojan
    Journal: Current Medicinal Chemistry, Vol. 31, Pages 1982-2002
    DOI: 10.2174/0109298673231106095141
    Publication Date: March 11, 2024
  • Title: Establishment of Cancer Gene Therapy
    Author: J. Trojan
    Journal: Cambridge Scholars Publishing
    Publication Date: March 2, 2023
  • Title: Neoplastic brain, glioblastoma and immunotherapy
    Author: J. Trojan et al.
    Journal: In: Brain and Spinal Tumors - Primary and Secondary, Ed. L.R. Morgan, F.B. Sarica, InTechOpen
    Publication Date: 2020
  • Title: In vitro technical aspects of Anti–Gene IGF-I vaccines against glioma
    Author: J. Trojan et al.
    Journal: IBR, Vol. 3(1), Pages 43-48
    Publication Date: 2019

Dr. WenQing Yang – Translational preclinical modelling for cancer and autoimmune diseases – Industry Leadership Excellence Award

Dr. WenQing Yang - Translational preclinical modelling for cancer and autoimmune diseases - Industry Leadership Excellence Award

ClinBridge Biotechnology Corporation Limited - China

Professional Profile

SCOPUS

ORCID

🎓 EARLY ACADEMIC PURSUITS

WenQing Yang, Ph.D., embarked on a distinguished academic journey that laid the foundation for his influential career in biomedical research. His early education was marked by a profound interest in understanding complex biological systems, which guided him through rigorous academic training. Dr. Yang’s academic pursuits provided him with a robust understanding of animal disease modeling and cancer pharmacology, paving the way for his future contributions in these fields.

💼 PROFESSIONAL ENDEAVORS

With over 30 years of experience, Dr. Yang has made significant strides in drug discovery and development. His professional career began with a focus on early-stage drug discovery, where he demonstrated exceptional skill in advancing drug candidates from discovery to clinical development. Dr. Yang's career spans roles in both large pharmaceutical companies and small biotech firms, showcasing his versatility and leadership. His tenure as Founder and Chief Scientific Officer at Clinbridge Biotech Co. Ltd has been pivotal in establishing the company’s research and discovery infrastructure, driving scientific programs, and fostering global collaborations.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Yang’s research has been instrumental in the areas of cancer pharmacology, immuno-oncology, and autoimmune diseases. His work encompasses a wide range of activities, from animal disease modeling and cancer immunotherapy discovery to novel therapeutic targets validation. Dr. Yang’s expertise in dissecting the tumor micro-environment and validating biomarkers has led to significant advancements in understanding and treating complex diseases. His contributions to translational research have been crucial in bridging the gap between Translational preclinical modelling for cancer and autoimmune diseases preclinical studies and clinical applications.

🏆 ACCOLADES AND RECOGNITION

Throughout his career, Dr. Yang has been recognized for his exceptional contributions to biomedical research and drug discovery. His leadership in advancing over 20 drug candidates to PCC nomination or IND filing, with 15 molecules progressing to clinical trials, highlights his impact on the field. His role in leading translational sciences at Simcere Pharma Group Ltd further solidified his reputation as a leader in drug development and Translational preclinical modelling for cancer and autoimmune diseases translational research.

🌍 IMPACT AND INFLUENCE

Dr. Yang’s influence extends globally, with his research impacting both academic and clinical settings. His efforts in advancing drug discovery and development have led to innovative therapeutic approaches in oncology and immuno-oncology. By establishing and leading scientific programs Translational preclinical modelling for cancer and autoimmune diseases at Clinbridge Biotech and Simcere Pharma, Dr. Yang has played a crucial role in shaping the future of drug discovery and translational medicine, driving forward new treatments and therapeutic strategies.

🏛️ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang’s legacy is characterized by his dedication to advancing biomedical research and drug discovery. His work has set new standards in cancer pharmacology, immuno-oncology, and autoimmune diseases. Looking ahead, Dr. Yang is poised to continue his impactful work, focusing on novel therapeutics and innovative research approaches. His commitment to scientific excellence and leadership will undoubtedly inspire future advancements in the field, ensuring that his contributions continue to benefit the biomedical community for years to come.

NOTABLE PUBLICATIONS